Today: 21 June 2026

SoFi stock rises as Trump’s 10% credit-card cap idea shakes lenders — what investors watch next

SoFi stock rises as Trump’s 10% credit-card cap idea shakes lenders — what investors watch next

SoFi shares rose 1.1% to $26.89 Tuesday afternoon, outperforming a 0.4% drop in the S&P 500 as investors assessed Trump’s proposed 10% cap on credit card interest rates. The policy push has rattled banks and payments firms, who warn it could restrict credit. Wall Street analysts see legal hurdles but say fintech lenders like SoFi could benefit if banks tighten lending. Focus turns to SoFi’s Jan. 30 earnings.
13 January 2026
·
ServiceNow stock drops as Oppenheimer trims target — what to watch before earnings

ServiceNow stock drops as Oppenheimer trims target — what to watch before earnings

ServiceNow shares fell 3.3% to $137.95 Tuesday after Oppenheimer cut its price target to $200, citing sector concerns ahead of earnings. Goldman Sachs began coverage with a Buy rating and $205 target, while Citi maintained its Buy and placed the stock on a 30-day catalyst watch. The iShares Expanded Tech-Software ETF dropped 2%. Investors remain cautious after ServiceNow’s $7.75 billion Armis acquisition.
13 January 2026
··
Ofwat warns on South East Water outage as Severn Trent, United Utilities shares fall

Ofwat warns on South East Water outage as Severn Trent, United Utilities shares fall

Around 25,000 homes in Kent and Sussex lost water after a new supply failure at South East Water, prompting Ofwat to flag concern and launch a review. Shares in Severn Trent, United Utilities, and Pennon fell up to 2.6% as scrutiny intensified. South East Water is using tankers and bottled-water stations while restoring pressure, with full service expected by Wednesday. Some homes have faced four days without water.
13 January 2026
···
AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

AbbVie shares fell 0.1% to $219.83 Tuesday after announcing a three-year U.S. pricing deal tied to tariff exemptions. The company also signed a $650 million licensing agreement with China’s RemeGen for rights to an experimental cancer drug and bought a manufacturing site in Arizona. Management is set to speak at the J.P. Morgan Healthcare Conference on Jan. 14.
13 January 2026
··
Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus

Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus

Alnylam shares fell 0.1% to $370.39 Tuesday afternoon after the company projected 2026 net product revenue between $4.9 billion and $5.3 billion. Preliminary 2025 sales were disclosed at $2.987 billion. Analysts remained mostly positive but flagged possible weakness for Amvuttra next quarter. The update came as Alnylam outlined its new five-year strategy at the J.P. Morgan Healthcare Conference.
13 January 2026
··
Ingenico’s WalletConnect tie-up brings stablecoin payments to in-store checkout

Ingenico’s WalletConnect tie-up brings stablecoin payments to in-store checkout

Ingenico said Tuesday it will enable stablecoin payments at checkout counters using WalletConnect Pay on its Android point-of-sale terminals. The feature will support five stablecoins and over 700 wallets, with fees expected below those of traditional card payments. Ingenico’s terminals operate in 120 countries, but the company did not say how many merchants will adopt the option immediately.
13 January 2026
····
Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

Ligand Pharmaceuticals shares fell 10.6% after the FDA extended its review of partner Travere’s Filspari label expansion, resetting the decision deadline to April 13. Travere shares dropped 19%. The FDA classified the latest filing as a “major amendment” but did not request new safety or manufacturing data. The broader biotech sector was little changed.
13 January 2026
···
Coca-Cola stock edges up after KO sets Feb. 10 earnings date; CAGNY appearance next

Coca-Cola stock edges up after KO sets Feb. 10 earnings date; CAGNY appearance next

Coca-Cola shares rose 0.5% to $70.83 Tuesday after the company set Feb. 10 for its Q4 and full-year earnings release and investor call. CEO-elect Henrique Braun and CFO John Murphy will speak at the CAGNY conference in Orlando on Feb. 17. Coke expects a $1 billion impairment charge in Q4 tied to its Africa bottling sale. PepsiCo shares gained 1.4% while the S&P 500 ETF slipped 0.4%.
13 January 2026
··
American Airlines stock drops 3.5% as Delta outlook and credit-card rate-cap worries hit airline shares

American Airlines stock drops 3.5% as Delta outlook and credit-card rate-cap worries hit airline shares

American Airlines shares fell 3.5% to $15.44 Tuesday, underperforming other major U.S. carriers as investors reacted to Delta’s profit forecast and concerns over a proposed 10% cap on credit-card interest rates. The cap could threaten airline loyalty program profits. American will report earnings Jan. 27, the same day the NTSB holds a hearing on a 2025 fatal crash involving one of its regional jets.
13 January 2026
·····
Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

Travere Therapeutics shares fell 19% Tuesday after the FDA extended its review of Filspari for broader use in kidney disease, pushing the decision deadline to April 13. The stock hit an intraday low of $22.35 before recovering. Travere forecast $127 million in Q4 U.S. net product sales and ended 2025 with $323 million in cash and equivalents. Analyst Joseph Schwartz warned a formal rejection from the FDA remains possible.
13 January 2026
··
Amphenol stock rises as Barclays, Citi and Truist lift targets after CommScope deal closes

Amphenol stock rises as Barclays, Citi and Truist lift targets after CommScope deal closes

Amphenol shares rose 2.2% to $148.28 Tuesday, bucking a broader market decline after finalizing its $10.5 billion acquisition of CommScope’s CCS business. Analysts at Barclays, Citi, and Truist raised price targets, citing expected sales growth and stronger demand. The company projects CCS will add $4.1 billion in 2026 sales and $0.15 to EPS, excluding costs. Quarterly earnings are due Jan. 28.
13 January 2026
···
1 … 870 871 872 873 874 … 2,088

Stock Market Today

  • Joby Aviation Stock Hits $10 Amid Air-Taxi Sector Volatility Ahead of Key FAA Tests
    June 20, 2026, 5:57 PM EDT. Joby Aviation's stock rebounded 6.5% to close at $10.00 on Thursday, marking a 9.3% rise since June 12 amid a holiday-shortened trading week. The company's progress toward FAA certification, cash reserves of $2.5 billion, and competition from Archer Aviation and Beta Technologies remain under investor scrutiny. Joby, developing electric vertical takeoff and landing (eVTOL) air taxis for short trips, faces challenges from regulatory approvals and market scalability. Despite rallying, the stock reflects investor patience on milestones rather than solid earnings. The stock's performance precedes Monday's market session, which will test the sustainability of recent gains in a broader cautious market environment influenced by geopolitical tensions and a stronger dollar.

Latest articles

Go toTop